People
Galectin Therapeutics names COO Harold H. Shlevin as next CEO
12 June 2018 -

Galectin Therapeutics Inc (NASDAQ: GALT) has appointed Dr Harold H. Shlevin as its new chief executive officer with effect from 6 July 2018, the company announced on Tuesday.

Shlevin, who currently serves as chief operating officer, will take over from Dr Peter G. Traber, who has tendered his resignation as president, CEO and chief medical officer.

Announcing the appointment, board chairman Richard Uihlein said that Dr Shlevin has extensive healthcare leadership and business development experience.

As CEO, he will be responsible for directing and overseeing the potential partnering of Galectin's NASH Phase 3 compound. In addition, he will oversee future NASH cirrhosis trials and is responsible for the company's clinical trials in cancer immunotherapy and any other potential new clinical trials in other indications.

Galectin has also engaged Back Bay Life Science Advisors to support the company and its management team in the exploration of strategic alternatives.

"We believe our NASH-CX Phase 2 trial was the first large, randomised clinical trial of any drug to demonstrate a clinically meaningful improvement in HVPG in NASH cirrhosis patients," Dr Shlevin said. "With our management team and other core team members and the board leadership under Dick Uihlein, I am confident in our ability to build value for our shareholders and advance GR-MD-02 to provide patients a treatment option for dealing with their NASH cirrhosis."

NASH cirrhosis is the final stage in the progression of liver disease non-alcoholic steatohepatitis (NASH).

Login
Username:

Password: